Disease landscape
Cystic Fibrosis
Constraints in access to cystic fibrosis treatment and diagnosis vary significantly in the region with the difference between the highest and the lowest-scoring country of about 25 points. The main reasons for poor V4 performance are low share of patients on triple combination CF therapy in all countries but Czechia and long time to availability.
Cross-Country
General GAP for Cystic Fibrosis
Compliance with guidelines
Clinical practice guidelines recommend the use of 5 the cystic fibrosis drugs considered in the project. Overall, at least 3 of them are available in V4 countries - compliance with the guidelines is assessed at 60%-80%.
From registration to reimbursement
Population burden
DALY* - Rate per 100k
Estimated values.
There is no data for the EU and Western Europe average.
*disability adjusted life-years
Target population
kaftrio
Drug access
Number of patients treated (2022)
Drug access
Population treated (%)
Main issues
- The average time to reimbursement for cystic fibrosis drugs in the V4 countries is 5.0 years. The difference between the shortest and the longest mean time to reimbursement between the countries is 1 year.
- Financing of the triple combination CF therapy either in regular reimbursement and early access programmes was introduced in V4 states in 2021 and in 2022 in all countries with very different results – from 21% of target population treated in Hungary to 83% of target population treated in in Czechia.
Project
We measured the gap in innovative drug access and diagnostics in selected therapeutic areas in the Visegrád (V4) countries (Poland, Hungary, Czechia and Slovakia).